AI assistant
Solid Biosciences Inc. — Director's Dealing 2021
Mar 25, 2021
33003_dirs_2021-03-25_e94527f3-80d0-4e3d-9194-171282077112.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2021-03-23
Reporting Person: Koppel Adam (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-23 | Common Stock | A | 869565 | $5.75 | Acquired | 7929918 | Indirect |
Footnotes
F1: Represents shares of common stock held directly by BCLS SB Investco, LP ("BCLS").
F2: Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3: On March 23, 2021, BCLS purchased 869,565 shares of common stock of the Issuer at a price per share of $5.75, pursuant to an underwritten public offering.